Episode 505 : ASCO 2026 - RAMPART

from The Uromigos · host The Uromigos

James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.

Episode metadata supplied by the publisher feed · Published May 30, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Episode 505 : ASCO 2026 - RAMPART

0:00 29:31

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Uromigos?

This episode is 29 minutes long.

When was this The Uromigos episode published?

This episode was published on May 30, 2026.

Can I download this The Uromigos episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!